The landscape of lymphoma treatment in Spain is undergoing a critically important conversion, driven by precision medicine, targeted therapies, and enhanced collaborative efforts. Dr. Armando López Guillermo, the elected president of the Spanish Society of Hematology and Hemotherapy (SEHH) and president of the Spanish group of lymphomas and autologous bone marrow transplantation (geltram), emphasized this evolution.

Collaborative Efforts: The Spanish Lymphomas Registry (Reinf)

A cornerstone of this progress is the Spanish Lymphomas Registry (Reinf). This initiative, updated during the XXVI Annual Gelthian Meeting, compiles clinical facts from over 29,000 patients across 40 hospitals. This extensive national database is crucial for understanding lymphoma trends and tailoring therapeutic strategies.

Clinical trials: Paving the Way for Improved Treatments

Geltram is actively coordinating 13 clinical trials focused on enhancing the treatment of common lymphoma subtypes. These trials include:

• Five trials on diffuse large B-cell lymphoma (DLBCL)
• Five trials on mantle cell lymphoma (MCL)
• two trials on Hodgkin lymphoma
• One trial on follicular lymphoma

Advances in Mantle Cell Lymphoma (MCL) Treatment

Dr. eva Giné, from the Clinic Hospital in Barcelona, highlighted the progress in MCL treatment, particularly the use of BTK inhibitors. These inhibitors target a key protein essential for tumor cell survival and are increasingly being used in first-line treatments.

these treatments are already beginning to be used in combination with immunoquimotherapy on the front line, and are displacing bone marrow transplantation in some cases.
Dr.Eva Giné, Clinic Hospital, Barcelona

Single-Cell Studies: Unlocking New Insights

Dr. miguel Alcoceba, coordinator of the pathology and Molecular Biology Working Group at the Salamanca University Hospital, presented the latest advancements in single-cell studies. This technology allows for the individual analysis of tumor cells, revealing subtle differences and information often missed by conventional techniques.

Follicular Lymphoma and Marginal Zone Lymphoma

Spain has enrolled 28 patients from 15 centers in a study focusing on indolent follicular lymphoma. Furthermore, updated data from the ‘IELSG48’ clinical trial, comparing zanubrutinib and Rituximab combination therapy with Rituximab alone, were presented for marginal zone lymphoma. Results from a real-world study involving 101 patients with relapsed or refractory marginal zone lymphoma treated with Zanubrutinib were also showcased.

Hodgkin Lymphoma: New Therapies and Treatment Strategies

Dr. Eva Domingo, coordinator of the Hodgkin Lymphoma Working Group at the hospitale-hospital Durán I Reynals in Barcelona, discussed the emergence of new targeted therapies for older patients with advanced Hodgkin lymphoma. The combination of these therapies in relapse cases is also showing promise, potentially avoiding the need for bone marrow transplants in certain situations. Additionally, research is underway to explore the possibility of omitting radiotherapy in initial stages of the disease without compromising treatment efficacy.

Phase II Trial: Brentuximab Vedotin in Hodgkin Lymphoma

Dr. Pilar Sarandeses,of the 12 de octubre University Hospital in Madrid and coordinator of the Geltamo Diagnostic Working Group,detailed the phase II ‘Brecellibet/Geltamo18-HL’ trial. This trial evaluates the use of Brentuximab Vedotin as a consolidation treatment in patients with classic Hodgkin lymphoma in relapse or refractory bone marrow who achieve a complete response after rescue therapy.